Navigation Links
Butrans® (Buprenorphine) Transdermal System CIII Pivotal Phase 3 Data Published in the Journal of Pain and Symptom Management
Date:10/26/2011

STAMFORD, Conn., Oct. 26, 2011 /PRNewswire/ -- A pivotal Phase 3 study of Butrans® (buprenorphine) Transdermal System CIII in opioid-naive patients with moderate-to-severe chronic low back pain demonstrated significantly lower "average pain over the last 24 hours" scores compared to placebo at the end of a 12-week, randomized, double-blind phase, in a study published in the online version of the September issue of the Journal of Pain and Symptom Management.

"These data are important in understanding the role of Butrans for opioid-naive patients with moderate-to-severe chronic pain requiring a continuous, around-the-clock opioid analgesic for an extended period of time," said Deborah Steiner, MD, MS, medical director at Purdue Pharma L.P.

The Butrans Transdermal System, approved by the U.S. Food and Drug Administration (FDA) in June 2010, is indicated for the management of moderate-to-severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time.  Butrans is the first transdermal system approved in the United States that delivers continuous release of the active ingredient, buprenorphine, for seven days.

Butrans is a Schedule III opioid prescription medication and can be abused in a manner similar to other opioid agonists, legal or illicit.  Working with the FDA, Purdue Pharma L.P. has developed a Risk Evaluation and Mitigation Strategy (REMS) for Butrans that includes a Medication Guide, Elements to Assure Safe Use, such as a healthcare provider training guide, and a timetable for submitting assessments of the REMS.  This information is available at www.Butransrems.com.

Butrans is contraindicated in patients who have significant respiratory depression, severe bronchial asthma, who have or are suspected o
'/>"/>

SOURCE Purdue Pharma L.P.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain
2. Purdue Pharma L.P. to Present Data From Clinical Program for Butrans™ (buprenorphine) Transdermal System CIII at PAINWeek® 2010
3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
4. Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial
5. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
6. Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
9. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
10. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
11. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015  Today, in final recognition of the ... Health Week, 1-800 Contacts is sharing how to keep ... lens wearers who do not properly care for their ... infections. Most contact lens wearers understand ... clean lens case is sometimes overlooked.  When proper steps ...
(Date:8/28/2015)... Aug. 28, 2015 Research ... of the "Investigation Report on China,s Ranibizumab Market, ... by Novartis, ranibizumab was approved by CFDA to treat ... only Lucentis, a product of Novartis, is available in ... first self- developed drug for the treatment of wet ...
(Date:8/28/2015)... Denmark and ATLANTA , August ... the US Food and Drug Administration (FDA) cleared the MagVita ... in adult patients who have failed to receive satisfactory improvement ... a non-invasive technique for stimulating neural tissue in the part ... Disorder. The procedure has been proven safe and effective and ...
Breaking Medicine Technology:1-800 Contacts Shares Tips on How to Clean Lens Cases 2Investigation Report on China's Ranibizumab Market, 2012-2019 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3
... Feb. 23 MAP,Pharmaceuticals, Inc. (Nasdaq: ... 3 clinical trial of Unit Dose Budesonide (UDB) ... The Company announced that the clinical,trial did not ... by,changes from baseline in nighttime and daytime composite ...
... BCRX ) today announced that the full ... peramivir in patients hospitalized for influenza was presented by ... Professor, Divisions of Infectious Diseases and Organ Transplantation at ... the XI International Symposium on Respiratory Viral Infections taking ...
Cached Medicine Technology:MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 2MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 3Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 2Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 3Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 4Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 5
(Date:8/28/2015)... ... August 28, 2015 , ... ... management, Decatur County Memorial Hospital recently transitioned management companies to partner with Wound ... Management for their outpatient wound center. , Transitioning wound care management providers ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately 2,000 ... Zoo to celebrate children helping children, a thank you to the many creative ... have contributed to the United Methodist initiative to end malaria deaths. , The ...
(Date:8/28/2015)... CA (PRWEB) , ... August 28, 2015 , ... An ... journey that local pizza maker Paul LaRocco has gone through to open a pizzeria ... approval and permitting process tends to take several months, but the current process, having ...
(Date:8/28/2015)... , ... August 28, 2015 , ... For Dallas, the ... taking part with their subsidiary USPI Tenet Health. , The American Heart Association hosts ... disease and stroke. They believe that together, a difference can be made. Walkers can ...
(Date:8/28/2015)... ... August 28, 2015 , ... As reported by Medical ... received FDA clearance for results that last for two years, the longest of any ... patients who are looking for a long-lasting, effective solution for their cellulite, according to ...
Breaking Medicine News(10 mins):Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3
... are resistant to androgen deprivation therapy are more invasive ... androgen dependent prostate cancers, UCLA cancer researchers have found. ... first, but they progress and become resistant over time. ... despite surgical or medical therapies that deplete testosterone. The ...
... of pure silica coated with an active material could ... other hazardous materials from water much more effectively and ... to researchers writing in the current issue of the ... Ping Chan of the Ian Wark Research Institute, at ...
... /PRNewswire-FirstCall/ - SXC Health Solutions, Inc.,("SXC" or the ... leading provider of,pharmacy benefits management services, announces that ... present at Raymond James, 29th,Annual Institutional Investors Conference ... SXC,s presentation will take place on Monday,March 3, ...
... work in humans , , WEDNESDAY, Feb. 20 (HealthDay News) -- ... Stanford University researchers report. , The use of neural cells ... the rats, physical abilities, according to the study, which is ... of Science ONE . The stroke damage induced by the ...
... HATBORO, Pa., Feb. 20 InfoLogix, Inc.,(Nasdaq: ... mobility,solutions for the healthcare and commercial industries, announced ... at the Growth & Value,Investor Conference to be ... on,February 27-28, 2008., (Logo: http://www.newscom.com/cgi-bin/prnh/20071101/NETH165LOGO ...
... to grow at a compound annual growth rate ... WALTHAM, Mass., Feb. 20 According to Millennium,Research Group,s Global ... report, the US hyaluronic acid,(HA) dermal filler market will grow ... through 2011., Growth in this market will be driven ...
Cached Medicine News:Health News:Hormone refractory prostate cancers more likely to spread to other organs 2Health News:Cleaner water through nanotechnology 2Health News:Stem Cells Repair Stroke Damage in Rats 2Health News:InfoLogix, Inc. to Present at the Growth & Investor Conference in Fort Lauderdale, FL 2Health News:InfoLogix, Inc. to Present at the Growth & Investor Conference in Fort Lauderdale, FL 3Health News:Hyaluronic Acid Dermal Filler Market Skyrockets 2
... 50/60 Hz, 100/120 V Fast - Powerful ... rotor spins up to 14,000 rpm (18,000 x g) ... Cell Virus Isolation Fits on crowded ... Comes complete with a 24-place aerosol-tight, autoclavable fixed-angle rotor ...
Inquire...
... designed to create the ideal environment for nucleic ... 99.9C) , Variable speed control (10 to ... it be for washing or hybridizing , ... inside the chamber, ,is situated above a touch ...
... HybriCycler Hybridization Oven with circular clear acrylic ... tubes. HC-3000 HybriCycler Oven features microprocessor operation ... feet balance the unit., Carousel rotates ... carousel is ,easily removable , Bottle ...
Medicine Products: